3rd Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$400,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Financial Institutions/Investments/Securities FIN

H.R. 4015 Corporate Governance Reform and Transparency Act of 2017 and oversight of proxy advisory firms

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
DAVID MARIN —

Contacted: Commerce, Dept of (DOC); White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC); SENATE

Bills named: H.R. 4015 (115th)

Trade (domestic/foreign) TRD

Trade issues related to generic medicines

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
DEBORAH AUTOR New —
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —
NIMISH SHAH —
PETER WALLACE New 2008 Legislative Correspondent, Rep. Ric Keller

Contacted: Health & Human Services, Dept of (HHS); Natl Economic Council (NEC); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Food & Drug Administration (FDA); White House Office; Office of Management & Budget (OMB)

Copyright/Patent/Trademark CPT

Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs, Hatch-Waxman Integrity Act of 2018, Patent Settlements

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —

Contacted: SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); White House Office; Natl Economic Council (NEC); Commerce, Dept of (DOC); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Health Issues HCR

Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
DEBORAH AUTOR New —
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —
PETER WALLACE New 2008 Legislative Correspondent, Rep. Ric Keller

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Management & Budget (OMB); SENATE; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Natl Economic Council (NEC); White House Office

Bills named: S. 974 (115th), H.R. 2051 (115th), H.R. 2212 (115th)

Budget/Appropriations BUD

Medicaid Rebate provision of the Bipartisan Budget Act of 2015

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —
PETER WALLACE New 2008 Legislative Correspondent, Rep. Ric Keller

Contacted: Commerce, Dept of (DOC); White House Office; SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Natl Economic Council (NEC)

Tariff (miscellaneous tariff bills) TAR

Tariff issues related to generic medicines

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
DEBORAH AUTOR New —
AKSHAI DATTA —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —
NIMISH SHAH —

Contacted: Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); SENATE; Natl Economic Council (NEC); Food & Drug Administration (FDA); White House Office; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN NV United Kingdom United Kingdom 100.0% —
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.